Bicycle Therapeutics announces first patient dosed in phase I dose escalation of BT5528 in combination with nivolumab

Bicycle Therapeutics, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, announced that the first patient has been dosed in a Phase I dose escalation of BT5528 in combination with nivolumab.